Chaput et al. [23] found that the expression levels of CDK17 are significantly increased in Alzheimer's disease and are associated with the mechanism to promote AD neurodegeneration and may inhibit the pathology development in AD, and Demirkan et al. [24], through a genome-wide association study, found that the CDK17 can be mapped to the glycerophospholipid metabolism pathway. Here, CDK17 is linked to early-onset autosomal dominant Alzheimer disease.